• LAST PRICE
    1.0700
  • TODAY'S CHANGE (%)
    Trending Down-0.0300 (-2.7273%)
  • Bid / Lots
    1.0600/ 3
  • Ask / Lots
    1.1700/ 10
  • Open / Previous Close
    1.0800 / 1.1000
  • Day Range
    Low 1.0500
    High 1.1300
  • 52 Week Range
    Low 0.7310
    High 2.2900
  • Volume
    129,580
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.1
TimeVolumeKRON
09:32 ET8041.08
09:33 ET2001.13
09:35 ET11001.08
09:39 ET3401.08
10:04 ET207391.05
10:08 ET82981.06
10:09 ET439001.05
10:15 ET101001.05
10:20 ET46431.05
10:22 ET1001.06
10:38 ET1131.06
10:58 ET2071.07
11:09 ET120501.07
11:18 ET1001.05
11:21 ET1911.05
11:34 ET2021.05
11:45 ET5001.0784
11:52 ET2761.06
11:56 ET2001.08
11:59 ET2761.06
12:10 ET7541.097
12:15 ET5001.08
12:21 ET3071.06
12:32 ET4001.07
12:39 ET5171.06
12:50 ET6671.0643
12:51 ET3351.06
12:57 ET98001.075
01:33 ET4951.0999
01:36 ET2001.07
01:42 ET3001.07
01:56 ET5001.079
02:45 ET13701.1
03:32 ET4851.1
03:57 ET2461.07
04:00 ET25811.07
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesKRON
Kronos Bio Inc
64.1M
-0.5x
---
United StatesCGTX
Cognition Therapeutics Inc
64.6M
-2.5x
---
United StatesOKYO
OKYO Pharma Ltd
50.4M
-0.1x
---
United StatesRZLT
Rezolute Inc
63.4M
-1.6x
---
United StatesKZR
Kezar Life Sciences Inc
61.8M
-0.7x
---
United StatesRTGN
RetinalGenix Technologies Inc
61.7M
-28.0x
---
As of 2024-02-24

Company Information

Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. It focuses on advancing two investigational compounds in clinical trials for patients with cancer. The Company’s product engine includes its proprietary small molecule microarray (SMM) screening platform, which provides the capability to map and target transcription regulatory networks (TRNs) in a differentiated manner to enable discovery of novel compounds and improve its ability to discover and optimize clinical development candidates. Its pipeline includes KB-0742 and Lanraplenib. KB-0742 is an oral cyclin dependent kinase 9 (CDK9) inhibitor for the treatment of MYC-amplified and other transcriptionally addicted solid tumors. Lanraplenib is a small molecule selective inhibitor targeting spleen tyrosine kinase (SYK), a critical node in a dysregulated TRN within acute myeloid leukemia (AML).

Contact Information

Headquarters
1300 S. El Camino Real, Suite 400SAN MATEO, CA, United States 94402
Phone
650-781-5200
Fax
302-636-5454

Executives

Non-Executive Independent Chairman of the Board
Arie Belldegrun
President, Chief Executive Officer, Director
Norbert Bischofberger
Interim Chief Financial Officer
Sandra Gardiner
Chief Scientific Officer
Christopher Dinsmore
Director
Joshua Kazam

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$64.1M
Revenue (TTM)
$4.0M
Shares Outstanding
58.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.81
EPS
$-2.08
Book Value
$4.29
P/E Ratio
-0.5x
Price/Sales (TTM)
16.0
Price/Cash Flow (TTM)
---
Operating Margin
-3,202.60%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.